• Bellberry Human Research Ethics Committee (HREC) has approved the HARNESS-1 trial
• Approval enables additional Australian clinical trial sites to participate
• Chris O'Brien Lifehouse and Austin Health to start-up upon governance approval

Race Oncology Ltd is pleased to announce that Bellberry Human Research Ethics Committee (HREC) has approved the Company's HARNESS-1 lung cancer clinical trial, enabling additional Australian clinical trial sites to participate. This approval follows the earlier approval granted by St Vincents Hospital (Melbourne) HREC for the lead clinical trial site, Monash Health. HARNESS-1 is evaluating the safety, tolerability and pharmacokinetics (PK) of RC220 (E,E-bisantrene) in combination with osimertinib (Tagrisso®, AstraZeneca) in patients with non-small cell lung cancer (NSCLC) harbouring activating epidermal growth factor receptor mutations (EGFRm). Bellberry ethics approval applies to Australian private hospital sites and eligible public hospital sites outside Victoria. Chris O'Brien Lifehouse will now progress to governance and start-up activities. St Vincents Hospital (Melbourne) HREC has also approved the inclusion of Austin Health (Victoria), which will similarly proceed with governance and start-up activities. Additional Australian sites are expected to be added to the study in the coming months as further governance approvals are received.